Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.
Identifieur interne : 000435 ( Main/Exploration ); précédent : 000434; suivant : 000436Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.
Auteurs : Richard H. Parrish [États-Unis] ; Danielle E. Pazdur ; Philip J. O'DonnellSource :
- Pharmacotherapy [ 0277-0008 ] ; 2006.
Descripteurs français
- KwdFr :
- Accident vasculaire cérébral (prévention et contrôle), Algie faciale (traitement médicamenteux), Analgésiques non narcotiques (usage thérapeutique), Anticoagulants (usage thérapeutique), Carbamazépine (usage thérapeutique), Femelle (MeSH), Fibrillation auriculaire (traitement médicamenteux), Humains (MeSH), Interactions médicamenteuses (MeSH), Rapport international normalisé (MeSH), Sujet âgé (MeSH), Thrombose (prévention et contrôle), Warfarine (usage thérapeutique).
- MESH :
- prévention et contrôle : Accident vasculaire cérébral, Thrombose.
- traitement médicamenteux : Algie faciale, Fibrillation auriculaire.
- usage thérapeutique : Analgésiques non narcotiques, Anticoagulants, Carbamazépine, Warfarine.
- Femelle, Humains, Interactions médicamenteuses, Rapport international normalisé, Sujet âgé.
English descriptors
- KwdEn :
- Aged (MeSH), Analgesics, Non-Narcotic (therapeutic use), Anticoagulants (therapeutic use), Atrial Fibrillation (drug therapy), Carbamazepine (therapeutic use), Drug Interactions (MeSH), Facial Pain (drug therapy), Female (MeSH), Humans (MeSH), International Normalized Ratio (MeSH), Stroke (prevention & control), Thrombosis (prevention & control), Warfarin (therapeutic use).
- MESH :
- chemical , therapeutic use : Analgesics, Non-Narcotic, Anticoagulants, Carbamazepine, Warfarin.
- drug therapy : Atrial Fibrillation, Facial Pain.
- prevention & control : Stroke, Thrombosis.
- Aged, Drug Interactions, Female, Humans, International Normalized Ratio.
Abstract
A 72-year-old Caucasian woman with paroxysmal atrial fibrillation had been taking warfarin therapy for 5 years with a stable international normalized ratio (INR). Her dentist then prescribed carbamazepine 200 mg/day to control facial nerve pain. At her next physician visit about 2 weeks after the start of the carbamazepine, the patient's INR had dropped from 3.3 to 1.3; she reported no contributing changes in her diet or warfarin dosage, nor had she taken other interacting drugs. Her warfarin dosage was increased, and the INR returned to the target range of 2.0-3.0 approximately 2 months later. The patient's INR remained stable for approximately 6 more months, until she had facial surgery. During that time, her warfarin was discontinued for 5 days, and the patient had stopped taking the carbamazepine because she had no pain. One month later, her INR increased from 2.2 to 3.6. She did not experience any thrombotic or hemorrhagic episodes. Warfarin undergoes hepatic metabolism through cytochrome P450 2C9, and carbamazepine induces this isoenzyme. Inducing warfarin metabolism necessitates an increase in the warfarin dosage to maintain the INR in the therapeutic target range. To our knowledge, this is the first report documenting the effect of the carbamazepine initiation and discontinuation in a patient receiving anticoagulation therapy with warfarin. In patients taking warfarin, clinicians should monitor the INR closely when carbamazepine is started or discontinued, or when either dosage is changed.
DOI: 10.1592/phco.26.11.1650
PubMed: 17064211
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.</title><author><name sortKey="Parrish, Richard H" sort="Parrish, Richard H" uniqKey="Parrish R" first="Richard H" last="Parrish">Richard H. Parrish</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Bon Secours St. Mary's Hospital, Richmond, Virginia 23226, USA. rhparrish2@yahoo.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacy, Bon Secours St. Mary's Hospital, Richmond, Virginia 23226</wicri:regionArea><wicri:noRegion>Virginia 23226</wicri:noRegion></affiliation></author><author><name sortKey="Pazdur, Danielle E" sort="Pazdur, Danielle E" uniqKey="Pazdur D" first="Danielle E" last="Pazdur">Danielle E. Pazdur</name></author><author><name sortKey="O Donnell, Philip J" sort="O Donnell, Philip J" uniqKey="O Donnell P" first="Philip J" last="O'Donnell">Philip J. O'Donnell</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17064211</idno><idno type="pmid">17064211</idno><idno type="doi">10.1592/phco.26.11.1650</idno><idno type="wicri:Area/Main/Corpus">000429</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000429</idno><idno type="wicri:Area/Main/Curation">000429</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000429</idno><idno type="wicri:Area/Main/Exploration">000429</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.</title><author><name sortKey="Parrish, Richard H" sort="Parrish, Richard H" uniqKey="Parrish R" first="Richard H" last="Parrish">Richard H. Parrish</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy, Bon Secours St. Mary's Hospital, Richmond, Virginia 23226, USA. rhparrish2@yahoo.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacy, Bon Secours St. Mary's Hospital, Richmond, Virginia 23226</wicri:regionArea><wicri:noRegion>Virginia 23226</wicri:noRegion></affiliation></author><author><name sortKey="Pazdur, Danielle E" sort="Pazdur, Danielle E" uniqKey="Pazdur D" first="Danielle E" last="Pazdur">Danielle E. Pazdur</name></author><author><name sortKey="O Donnell, Philip J" sort="O Donnell, Philip J" uniqKey="O Donnell P" first="Philip J" last="O'Donnell">Philip J. O'Donnell</name></author></analytic><series><title level="j">Pharmacotherapy</title><idno type="ISSN">0277-0008</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Analgesics, Non-Narcotic (therapeutic use)</term><term>Anticoagulants (therapeutic use)</term><term>Atrial Fibrillation (drug therapy)</term><term>Carbamazepine (therapeutic use)</term><term>Drug Interactions (MeSH)</term><term>Facial Pain (drug therapy)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>International Normalized Ratio (MeSH)</term><term>Stroke (prevention & control)</term><term>Thrombosis (prevention & control)</term><term>Warfarin (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Accident vasculaire cérébral (prévention et contrôle)</term><term>Algie faciale (traitement médicamenteux)</term><term>Analgésiques non narcotiques (usage thérapeutique)</term><term>Anticoagulants (usage thérapeutique)</term><term>Carbamazépine (usage thérapeutique)</term><term>Femelle (MeSH)</term><term>Fibrillation auriculaire (traitement médicamenteux)</term><term>Humains (MeSH)</term><term>Interactions médicamenteuses (MeSH)</term><term>Rapport international normalisé (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Thrombose (prévention et contrôle)</term><term>Warfarine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Analgesics, Non-Narcotic</term><term>Anticoagulants</term><term>Carbamazepine</term><term>Warfarin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term><term>Facial Pain</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Stroke</term><term>Thrombosis</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Accident vasculaire cérébral</term><term>Thrombose</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Algie faciale</term><term>Fibrillation auriculaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Analgésiques non narcotiques</term><term>Anticoagulants</term><term>Carbamazépine</term><term>Warfarine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>International Normalized Ratio</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Rapport international normalisé</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A 72-year-old Caucasian woman with paroxysmal atrial fibrillation had been taking warfarin therapy for 5 years with a stable international normalized ratio (INR). Her dentist then prescribed carbamazepine 200 mg/day to control facial nerve pain. At her next physician visit about 2 weeks after the start of the carbamazepine, the patient's INR had dropped from 3.3 to 1.3; she reported no contributing changes in her diet or warfarin dosage, nor had she taken other interacting drugs. Her warfarin dosage was increased, and the INR returned to the target range of 2.0-3.0 approximately 2 months later. The patient's INR remained stable for approximately 6 more months, until she had facial surgery. During that time, her warfarin was discontinued for 5 days, and the patient had stopped taking the carbamazepine because she had no pain. One month later, her INR increased from 2.2 to 3.6. She did not experience any thrombotic or hemorrhagic episodes. Warfarin undergoes hepatic metabolism through cytochrome P450 2C9, and carbamazepine induces this isoenzyme. Inducing warfarin metabolism necessitates an increase in the warfarin dosage to maintain the INR in the therapeutic target range. To our knowledge, this is the first report documenting the effect of the carbamazepine initiation and discontinuation in a patient receiving anticoagulation therapy with warfarin. In patients taking warfarin, clinicians should monitor the INR closely when carbamazepine is started or discontinued, or when either dosage is changed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17064211</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0277-0008</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>11</Issue><PubDate><Year>2006</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Pharmacotherapy</Title><ISOAbbreviation>Pharmacotherapy</ISOAbbreviation></Journal><ArticleTitle>Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.</ArticleTitle><Pagination><MedlinePgn>1650-3</MedlinePgn></Pagination><Abstract><AbstractText>A 72-year-old Caucasian woman with paroxysmal atrial fibrillation had been taking warfarin therapy for 5 years with a stable international normalized ratio (INR). Her dentist then prescribed carbamazepine 200 mg/day to control facial nerve pain. At her next physician visit about 2 weeks after the start of the carbamazepine, the patient's INR had dropped from 3.3 to 1.3; she reported no contributing changes in her diet or warfarin dosage, nor had she taken other interacting drugs. Her warfarin dosage was increased, and the INR returned to the target range of 2.0-3.0 approximately 2 months later. The patient's INR remained stable for approximately 6 more months, until she had facial surgery. During that time, her warfarin was discontinued for 5 days, and the patient had stopped taking the carbamazepine because she had no pain. One month later, her INR increased from 2.2 to 3.6. She did not experience any thrombotic or hemorrhagic episodes. Warfarin undergoes hepatic metabolism through cytochrome P450 2C9, and carbamazepine induces this isoenzyme. Inducing warfarin metabolism necessitates an increase in the warfarin dosage to maintain the INR in the therapeutic target range. To our knowledge, this is the first report documenting the effect of the carbamazepine initiation and discontinuation in a patient receiving anticoagulation therapy with warfarin. In patients taking warfarin, clinicians should monitor the INR closely when carbamazepine is started or discontinued, or when either dosage is changed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parrish</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Bon Secours St. Mary's Hospital, Richmond, Virginia 23226, USA. rhparrish2@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazdur</LastName><ForeName>Danielle E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>O'donnell</LastName><ForeName>Philip J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacotherapy</MedlineTA><NlmUniqueID>8111305</NlmUniqueID><ISSNLinking>0277-0008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018712" MajorTopicYN="N">Analgesics, Non-Narcotic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005157" MajorTopicYN="N">Facial Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019934" MajorTopicYN="N">International Normalized Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>10</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17064211</ArticleId><ArticleId IdType="doi">10.1592/phco.26.11.1650</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="O Donnell, Philip J" sort="O Donnell, Philip J" uniqKey="O Donnell P" first="Philip J" last="O'Donnell">Philip J. O'Donnell</name><name sortKey="Pazdur, Danielle E" sort="Pazdur, Danielle E" uniqKey="Pazdur D" first="Danielle E" last="Pazdur">Danielle E. Pazdur</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Parrish, Richard H" sort="Parrish, Richard H" uniqKey="Parrish R" first="Richard H" last="Parrish">Richard H. Parrish</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SuicidDentistV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000435 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000435 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SuicidDentistV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17064211
|texte= Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17064211" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SuicidDentistV1
| This area was generated with Dilib version V0.6.39. |  |